AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

03 Aug 2023 05:30:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023

13 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response

26 Jun 2023 05:30:00 By Nasdaq GlobeNewswire

Agios to Present at the Goldman Sachs Global Healthcare Conference on June 15, 2023

05 Jun 2023 06:00:00 By Nasdaq GlobeNewswire

Agios Appoints Catherine Owen to Board of Directors

25 May 2023 06:00:00 By Nasdaq GlobeNewswire

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

11 May 2023 09:00:00 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2023 Financial Results

04 May 2023 06:00:02 By Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 16, 2023

25 Apr 2023 06:00:01 By Nasdaq GlobeNewswire

Agios Appoints Jeffrey Capello to Board of Directors

19 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023

13 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Agios Publishes 2023 Environmental, Social and Governance (ESG) Report

03 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Agios to Participate in March Investor Conferences

02 Mar 2023 07:26:35 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023

02 Feb 2023 06:00:01 By Nasdaq GlobeNewswire

Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company’s Vision to Transform Patient Outcomes in Rare Diseases

08 Jan 2023 19:00:00 By Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

03 Jan 2023 16:57:50 By Nasdaq GlobeNewswire

Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023

21 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Agios Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

11 Dec 2022 18:00:00 By Nasdaq GlobeNewswire

Agios Presents Updated PYRUKYND® (mitapivat) Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis and Ineffective Erythropoiesis in Non-transfusion-dependent α- and β-Thalassemia at 64th ASH Annual Meeting and Exposition

10 Dec 2022 17:30:00 By Nasdaq GlobeNewswire

Agios Appoints Tsveta Milanova as Chief Commercial Officer

06 Dec 2022 06:00:00 By Nasdaq GlobeNewswire